



EndoPredict®



EndoPredict:  
Helping guide confident  
treatment decisions

For ER+, HER2- early-stage breast cancer

AUSTRALIAN

 **Clinicallabs**

ER+, estrogen receptor-positive; HER2-, human epidermal growth factor receptor 2-negative.

 **myriad**  
WHEN DECISIONS MATTER®

# What is EndoPredict®?

After learning you have breast cancer, it can be hard to understand all of your options for testing and treatment. Using your first biopsy, the amount of protein made by different genes was checked. These genes were:

- ① Estrogen receptor, or *ER*
- ① Progesterone receptor (pro-JES-tuh-rohn re-SEP-tuhr), or *PR*
- ① Human epidermal growth factor receptor 2, or *HER2*

Knowing whether your tumour makes these proteins helps your doctor treat your breast cancer. Tumours that make the ER protein but not the HER2 protein are called ER positive (or ER+) and HER2 negative (or HER2-). For ER+ and HER2- tumours, more testing can help determine the best course of treatment.

## EndoPredict is a test for patients with ER+, HER2- breast cancer in early stages

EndoPredict calculates the chance that your cancer will return in the 10 years after treatment, offering important information about how aggressive your cancer is. Knowing this information can help you and your doctor make well-informed choices about your treatment.

### Why does your doctor trust EndoPredict?

- ① EndoPredict provides highly accurate test results for confident, long-term decision-making.
- ① It uses genetic information and other tumour features to calculate your personal results.
- ① Medical guidelines include EndoPredict.
- ① EndoPredict accurately identifies more patients who may safely forgo chemotherapy.
- ① EndoPredict is offered by Myriad, a company that has been a trusted name in diagnostic testing for over 25 years.

## Knowing your risk is important for your treatment

After surgery, you will make treatment choices with the goal of lowering the chance that your cancer will return, or recur, in the future. For patients, like you, who have ER+ breast cancer, endocrine therapy is standard, or routine. It can lower the risk of the cancer returning—also called the risk of recurrence—by almost half. Some patients will receive both endocrine therapy and chemotherapy. Your doctor will weigh several factors to decide if adding chemotherapy would benefit you further.

## What do your EndoPredict test results mean?

The EndoPredict report provides details about your specific cancer. It shows the risk of your cancer returning in the 10 years after treatment if you do not have chemotherapy. Your results will clearly note whether you are **low risk** or **high risk**.

- ◆ A **low-risk** result means that if you do not have chemotherapy, the risk of your cancer returning within 10 years is **low**.
- ◆ A **high-risk** result means that if you do not have chemotherapy, the risk of your cancer returning within 10 years is **high**.

## Creating a treatment plan that's right for you



For patients who have a **long-term risk of recurrence that is low**, adding chemotherapy is unlikely to improve the absolute benefit by much.

For patients who have a **long-term risk of recurrence that is high**, adding chemotherapy may help significantly lower the risk.





Australian Clinical Labs is one of the largest pathology providers in Australia. Our 90 labs perform close to 8 million episodes a year.

At Clinical Labs, we aspire to provide leadership and diagnostic excellence across all of our specialties, and our commitment to molecular cancer testing is no exception. In addition to leading the industry in traditional molecular analysis with ground-breaking core laboratories, our genetics test centres offer an innovative platform where our pathologists focus their expertise on a comprehensive testing selection dedicated exclusively to oncology.



Myriad, the Myriad logo, EndoPredict and the EndoPredict logo are either trademarks or registered trademarks of Myriad Genetics Inc. in the United States and other jurisdictions. Copyright © 2018 Myriad Genetics, Inc. All rights reserved. | EPPATBRO/06-18

1300 453 688  
[clinallabs.com.au](http://clinallabs.com.au)